{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T23:23:23Z","timestamp":1794525803540,"version":"4.9.1"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,2,13]],"date-time":"2009-02-13T00:00:00Z","timestamp":1234483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Neuroscience &amp; Therapeutics"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:p>This is the report of an open label clinical trial to evaluate the effects of nabilone, an endocannabinoid receptor agonist, on treatment\u2010resistant nightmares in patients diagnosed with posttraumatic stress disorder (PTSD). Methods: Charts of 47 patients diagnosed with PTSD and having continuing nightmares in spite of conventional antidepressants and hypnotics were reviewed after adjunctive treatment with nabilone was initiated. These patients had been referred to a psychiatric specialist outpatient clinic between 2004 and 2006. The majority of patients (72%) receiving nabilone experienced either cessation of nightmares or a significant reduction in nightmare intensity. Subjective improvement in sleep time, the quality of sleep, and the reduction of daytime flashbacks and nightsweats were also noted by some patients. The results of this study indicate the potential benefits of nabilone, a synthetic cannabinoid, in patients with PTSD experiencing poor control of nightmares with standard pharmacotherapy. This is the first report of the use of nabilone (Cesamet; Valeant Canada, Ltd., Montreal, Canada) for the management of treatment\u2010resistant nightmares in PTSD.<\/jats:p>","DOI":"10.1111\/j.1755-5949.2008.00071.x","type":"journal-article","created":{"date-parts":[[2009,2,13]],"date-time":"2009-02-13T12:30:51Z","timestamp":1234528251000},"page":"84-88","source":"Crossref","is-referenced-by-count":249,"title":["The Use of a Synthetic Cannabinoid in the Management of Treatment\u2010Resistant Nightmares in Posttraumatic Stress Disorder (PTSD)"],"prefix":"10.1111","volume":"15","author":[{"given":"George A.","family":"Fraser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,2,13]]},"reference":[{"key":"e_1_2_8_2_2","volume-title":"Diagnostic and statistical manual of mental disorders, DSM\u2010IV\u2010TR","year":"2000"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1995.03950240066012"},{"key":"e_1_2_8_4_2","article-title":"Posttraumatic Stress Disorder in Canada","author":"Van Ameringen M","year":"2009","journal-title":"CNS Neurosci & Ther"},{"issue":"2","key":"e_1_2_8_5_2","first-page":"57S","article-title":"Clinical practice guidelines. Management of anxiety disorders","volume":"51","year":"2006","journal-title":"Can J Psychiatry"},{"key":"e_1_2_8_6_2","first-page":"58","volume-title":"Post\u2010traumatic and acute stress disorders: The latest assessment and treatment strategies, 4th Edition","author":"Friedman M","year":"2006"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/comp.2000.16568"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-6185(02)00093-2"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1364.053"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1037\/1040-3590.9.4.445"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008877-200509000-00005"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature00839"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm803"},{"key":"e_1_2_8_14_2","doi-asserted-by":"crossref","first-page":"7A","DOI":"10.1155\/2005\/169093","article-title":"Preclinical science regarding cannabinoids as analgesics: An overview","volume":"10","author":"Lynch ME","year":"2005","journal-title":"Pain Res Manage"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.06.006"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25509"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300655"},{"key":"e_1_2_8_18_2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0026-895X(25)09876-1","article-title":"Determination and characterization of a cannabinoid receptor in rat brain","volume":"34","author":"Devane WA","year":"1988","journal-title":"Mol Pharmacol"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.54.2.161"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/346561a0"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.3.2"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2006.02.001"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2006.00085.x"},{"key":"e_1_2_8_24_2","first-page":"2218","article-title":"Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity\u2010related pain. A double\u2010blind placebo\u2010controlled cross\u2010over trial","volume":"20","author":"Wissel J","year":"2006","journal-title":"J Neurol"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1981.tb02618.x"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1981.tb02617.x"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105051541"},{"key":"e_1_2_8_28_2","article-title":"Nabilone and posttraumatic stress disorder in a user of therapeutic marijuana","author":"Bartolucci G","year":"2004","journal-title":"Four Zero One Pharma"},{"key":"e_1_2_8_29_2","unstructured":"CESAMET\u2122 (nabilone) Product Monograph. Valeant Canada Ltd. Montreal Quebec Canada 2006."}],"container-title":["CNS Neuroscience &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-5949.2008.00071.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-5949.2008.00071.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T18:08:19Z","timestamp":1738951699000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-5949.2008.00071.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,13]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1111\/j.1755-5949.2008.00071.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-5949.2008.00071.x","archive":["Portico"],"relation":{},"ISSN":["1755-5930","1755-5949"],"issn-type":[{"value":"1755-5930","type":"print"},{"value":"1755-5949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,13]]}}}